AMC

in page functions

28 March 2014

Pneumo Strategic Demand Forecast - Version 8_0

Published 28 March 2014 PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast Version 8.0. This version 8.0 is issued in accordance with the GAVI Forecasting Standard Operating Procedure.

21 March 2014

IAC Members

List of IAC members.

01 November 2013

Pneumococcal AMC OECD GDP Deflator Data

Pneumococcal AMC: OECD GDP Deflator Data Purpose: As per the Pneumococcal AMC Inflation Review Application Process, listed below is the OECD GDP Deflator to be used to calculate an inflation adjustment request. BASE QTR Q2-2009 Q2-2010 Q2-2011 Q2-2012 Q2-2013 Q2-2014 Q2-2015 Q2-2016 Q2-2017 Q2-2018 Q2-2019 Q2-2020 Q2-2

28 June 2013

Remaining AMC offer amount: June 2013

Remaining AMC offer amount: June 2013

29 April 2013

2013 Pneumococcal AMC Annual Report

The 2013 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2012 to 31 March 2013. During this period a third tender was issued in response to the high level of country demand and eight countries introduced pneumococcal vaccines procured through the AMC, taking the total to 24 introductions by March 2013.

09 August 2012

Pneumo Strategic Demand Forecast - Version 5_0 – Published 13 August 2012

ACCELERATE VACCINE INTRODUCTION – PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast (Required Supply) Version 5.0 – updated in March 2012 Published – 13 August 2012 This version 5.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure.

19 June 2012

Remaining AMC offer amount: June 2012

Remaining AMC offer amount: June 2012

01 June 2012

2012 Pneumococcal AMC Annual Report

The 2012 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2011 to 31 March 2012. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.

22 August 2011

Manufacturers FAQs

Frequently asked questions about Advance Market Commitments for vaccines for manufacturers.

16 June 2011

Remaining AMC offer amount: June 2011

The official formal notification of the remaining AMC Offer Amount.

01 April 2011

2011 Pneumococcal AMC Annual Report

The 2011 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2010 to 31 March 2011.

11 March 2011

Pneumo SDF version 3.0 – published on 11 March 2011

This version 3.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure. The forecast captures all AMC‐eligible demand including countries that: introduce with GAVI support, graduate from GAVI support, and are fully self-financed.

09 March 2011

AMC Legal Agreements: detailed list of modifications

List of modifications to the AMC legal agreements.

07 March 2011

Revised AMC offer agreement

 

Offer agreement relating to the Advance Market Commitment for pneumococcal vaccines.

07 March 2011

Revised AMC procedures memorandum

This Procedures Memorandum describes the procedures that would be applicable to any AMC.

07 March 2011

AMC deed of amendment and restatement

AMC deed of amendment and restatement relating to the Advance Market Commitment for pneumococcal vaccines offer agreement, IAC Charter & bylaws and procedures memorandum orginally dated 12 June 2009.

29 October 2010

AMC Baseline Study

The AMC Baseline Study presents an innovative new approach to public health funding as a way of stimulating and accelerating the development and manufacture of vaccines for developing countries.

01 September 2010

Serotype Replacement Note - Prepared by the IAC

The serotype replacement issue arises from extensive use of pneumococcal conjugate vaccine, which is expected to result in some increase of disease occurence due to serotypes not in the vaccine. This raises question whether the increases could reach a point where the benefit of the vaccine is lost, or the increases will be small relative to the decline in vaccine type disease.

23 August 2010

AMC IAC eligibility determination meeting: 23 August 2010

The purpose of the meeting was to review Pfizer’s application for AMC eligibility for Prevenar 13 and determine if the candidate vaccine met the TPP for the AMC.

29 July 2010

Pneumococcal AMC Inflation Review Application Process

The process for manufacturers interested in submitting an Inflation Review Application.

16 June 2010

Remaining AMC offer amount 2010

The official formal notification of the remaining AMC Offer Amount.

16 April 2010

PneumoADIP

PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health, supported by a $30 million grant from the GAVI Alliance.

16 April 2010

Minutes from AMC Eligibility Determination Meeting April 2010

Minutes from AMC Eligibility Determination Meeting held in London, UK on 16 April 2010.

31 March 2010

2010 Pneumococcal AMC Annual Report

This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC since the signature of the legal agreements on 12 June 2009 up until 31 March 2010. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 13 April 2010.

12 November 2009

IAC Members 2009

List of IAC members.

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please

Searching... One moment please




close icon

modal window here